{"id":39717,"date":"2017-07-03T07:01:18","date_gmt":"2017-07-03T11:01:18","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=39717"},"modified":"2017-07-03T07:01:19","modified_gmt":"2017-07-03T11:01:19","slug":"neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717","title":{"rendered":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study"},"content":{"rendered":"<p style=\"text-align: justify;\">The shares of<strong> Neothetics Inc (NASDAQ:NEOT) <\/strong>declined by 24%.This was brought forward by the announcement the provider made citing that it received disappointing results from a phase II proof-of-concept study. This study was carried out in a bid to evaluate the company\u2019s lead candidate, LIPO-202. Neothetics Inc wanted to investigate on the capability of this product towards cutting down on the submental subcutaneous fat.<\/p>\n<p style=\"text-align: justify;\">It is a matter that has raised major concerns among most of the interested parties. This was absurd considering that Zacks classified Medical-Drugs performed well. That is looking at the 8% increase, yet this was over the same period of time.<\/p>\n<p style=\"text-align: justify;\">On Dec 2016, the phase II study was carried out in a bid to evaluate the safety as well as the efficacy of two doses of LIPO-202.It was definitely to be put in comparison to placebo in a move to assess its impact in terms of its capabilities to reduce the submental bulging that is usually caused by the subcutaneous fat.<\/p>\n<p style=\"text-align: justify;\">According to <a href=\"https:\/\/finance.yahoo.com\/news\/neothetics-apos-fat-reduction-candidate-172005462.html\" target=\"_blank\" rel=\"noopener\">Yahoo,<\/a> this study has enrolled 162 patients at 12 sites and that is of course across the United States of America. They were reportedly served with subcutaneous injections of LIPO-202 .This was also carried out with a placebo, and for every eight weeks it was done once.<\/p>\n<p style=\"text-align: justify;\">The safety and efficacy measurements associated with the endpoints turned out to be a major disappointment. This was after showcasing failure towards providing the much anticipated improvements on any efficacy towards facing out the submental fat.<\/p>\n<p style=\"text-align: justify;\">One of the company\u2019s top executive in speaking to journalists stated, \u201cWe remind investors that in 2015, the company had conducted two pivotal phase III studies, evaluating LIPO-202 for the decrease of central abdominal bulging due to subcutaneous fat. These studies also failed to meet their co-primary composite or secondary endpoints and showed near identical results compared to placebo with no bias in sites or subgroups.\u201d<\/p>\n<p style=\"text-align: justify;\">Neothetics Inc has given its statement saying that it will continue with its great dedication to work and that soon it might be unveiling its future plans.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The shares of Neothetics Inc (NASDAQ:NEOT) declined by 24%.This was brought forward by the announcement the provider made citing that it received disappointing results from [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":39724,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12743,12742,12741],"stock_ticker":[],"class_list":["post-39717","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqneot","tag-neothetics-inc","tag-neothetics-inc-nasdaqneot","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The shares of Neothetics Inc (NASDAQ:NEOT) declined by 24%.This was brought forward by the announcement the provider made citing that it received disappointing results from [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-03T11:01:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-07-03T11:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study\",\"datePublished\":\"2017-07-03T11:01:18+00:00\",\"dateModified\":\"2017-07-03T11:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg\",\"keywords\":[\"NASDAQ:NEOT\",\"Neothetics Inc\",\"Neothetics Inc (NASDAQ:NEOT)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\",\"name\":\"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg\",\"datePublished\":\"2017-07-03T11:01:18+00:00\",\"dateModified\":\"2017-07-03T11:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg\",\"width\":300,\"height\":168},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717","og_locale":"en_US","og_type":"article","og_title":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR","og_description":"The shares of Neothetics Inc (NASDAQ:NEOT) declined by 24%.This was brought forward by the announcement the provider made citing that it received disappointing results from [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-07-03T11:01:18+00:00","article_modified_time":"2017-07-03T11:01:19+00:00","og_image":[{"width":300,"height":168,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study","datePublished":"2017-07-03T11:01:18+00:00","dateModified":"2017-07-03T11:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg","keywords":["NASDAQ:NEOT","Neothetics Inc","Neothetics Inc (NASDAQ:NEOT)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717","url":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717","name":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg","datePublished":"2017-07-03T11:01:18+00:00","dateModified":"2017-07-03T11:01:19+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39723-images__5_.jpeg","width":300,"height":168},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/neothetics-inc-nasdaqneot-hit-by-disappointment-after-its-fat-reduction-candidate-showcases-poor-results-in-phase-ii-study-39717#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Neothetics Inc (NASDAQ:NEOT) Hit By Disappointment After Its Fat Reduction Candidate Showcases Poor Results In Phase II Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=39717"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39717\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/39724"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=39717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=39717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=39717"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=39717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}